$2.52
-0.0100-0.40%
Pre-Market: 4:09 PM EDT
15 minutes delayed
Oramed Pharmaceuticals
ORMPNASDAQ
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock, Analyst Ratings, Price Targets, Forecasts
Oramed Pharmaceuticals Inc has a consensus price target of $20.5 based on the ratings of 5 analysts. The high is $30 issued by Aegis Capital on May 16, 2022. The low is $2 issued by Canaccord Genuity on May 17, 2023. The 3 most-recent analyst ratings were released by Canaccord Genuity, Aegis Capital, and Cantor Fitzgerald on May 17, 2023, May 16, 2022, and February 18, 2022, respectively. With an average price target of $17.33 between Canaccord Genuity, Aegis Capital, and Cantor Fitzgerald, there's an implied 587.83% upside for Oramed Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Aegis Capital
Cantor Fitzgerald
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Oramed Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/20/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Neutral | Get Alert |
| 05/17/2023 | Buy Now | -20.63% | Canaccord Genuity | Edward Nash | $3 → $2 | Maintains | Hold | Get Alert |
| 01/17/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 01/12/2023 | Buy Now | — | Canaccord Genuity | Edward Nash | — | Downgrade | Buy → Hold | Get Alert |
| 05/16/2022 | Buy Now | 1090.48% | Aegis Capital | Nathan Weinstein | $35 → $30 | Maintains | Buy | Get Alert |
| 02/18/2022 | Buy Now | 693.65% | Cantor Fitzgerald | Charles Duncan | → $20 | Initiates | → Overweight | Get Alert |
| 11/30/2021 | Buy Now | 1169.84% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 11/29/2021 | Buy Now | 1169.84% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 11/02/2021 | Buy Now | 1288.89% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
| 07/29/2021 | Buy Now | 1090.48% | Canaccord Genuity | — | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Oramed Pharmaceuticals (ORMP) stock?
The latest price target for Oramed Pharmaceuticals (NASDAQ:ORMP) was reported by HC Wainwright & Co. on May 20, 2024. The analyst firm set a price target for $0.00 expecting ORMP to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?
The latest analyst rating for Oramed Pharmaceuticals (NASDAQ:ORMP) was provided by HC Wainwright & Co., and Oramed Pharmaceuticals reiterated their neutral rating.
When was the last upgrade for Oramed Pharmaceuticals (ORMP)?
There is no last upgrade for Oramed Pharmaceuticals
When was the last downgrade for Oramed Pharmaceuticals (ORMP)?
The last downgrade for Oramed Pharmaceuticals Inc happened on January 17, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Oramed Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on May 20, 2024 so you should expect the next rating to be made available sometime around May 20, 2025.
Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a reiterated with a price target of $0.00 to $0.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.